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INTRODUCTION 
 Cerebrovascular diseases rank first in frequency and important among all 
neurologic diseases.  It is the second cause of mortality in the World.  A stroke 
or cerebrovascular accident is defined by the abrupt onset of a neurologic deficit 
that is attributable to a focal vascular cause. 
 80% of stroke is ischaemic and remaining 20% is due to haemorrhage.   
Intracranial haemorrhage includes: 
1. Intraparenchymal haemorrhage 
2. Intraventricular haemorrhage 
3. Subarachnoid haemorrhage 
There is 2 – 3 fold increased risk of intraparenchymal haemorrhage in 
Asians and Blacks. 
Many controversies surround the management of patients with ICH in 
large part because of paucity of prospective randomized controlled trial data that 
might more rationally guide therapy.  These controversies include management 
of hypertension, treatment of raised ICP and appropriate use of surgical 
techniques.  Since there is no sufficiently efficacious therapy for haemorrhage 
induced cerebral injury, prevention is the mainstay of treatment particularly 
hypertension.  It is appropriate to think in terms of pathophysiology to guide 
management decisions.  It would be useful, therefore, to know something about 
the time, course and prognosis of ICH. 
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Various factors have been identified as predicting outcome including age, 
gender, race, initial MAP, temperature, volume of bleed, site of bleed, 
intraventricular extension, mass effect and initial level of consciousness. 
This study is done to evaluate and discuss the significances of various 
factors in predicting 30 day mortality and morbidity of patients with non-
traumatic intraparenchymal haemorrhage in hypertension and non-hypertension 
haemorrhage stroke. 
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AIM OF THE STUDY 
1. To evaluate the prognostic factors in predicting 30 day outcome in 
patients with non traumatic intraparenchymal haemorrhage admitted to 
medical wards in the Government General Hospital, Chennai. 
2. To find out the prognostic significance of: 
a. Age 
b. Temperature 
c. Mean arterial pressure 
d. GCS score at admission 
e. Volume of Bleed 
f. Location of Bleed 
g. Intraventricular haemorrhage 
in predicting 30 day outcome assessed by NIHSS score in patients 
with non-traumatic intraparenchymal haemorrhage admitted to the 
medical wards in the Government General Hospital, Chennai. 
3. To compare the results with that one reported in literature.   
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REVIEW OF LITERATURE 
HISTORICAL REVIEW OF LITERATURE 
 
HIPPOCRATES 
 
GALEN 
 Stroke history dates back to Hippocrates and Galen who named at 
‘apoplexy’ a term that physicians applied to anyone suddenly struck down with 
paralysis but could not explain its pathology. 
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JOHANN JACOBB WEPFER 
 
 The first person to investigate the pathological signs of apoplexy was 
Johann Jacobb Wepfer.  Born in Schaffhausen, Switzerland, in 1620, Wepfer 
studied medicine and was the first to identify postmortem signs of bleeding in 
brains of patients who died of apoplexy.  From autopsy studies, he gained 
knowledge of carotid and vertebral arteries that supply the brain.  He was the 
first person to suggest that apoplexy in addition to being caused by bleeding in 
the brain, could be caused by blockage of one of the main arteries supplying 
blood to the brain.  Thus, stroke came to be known as CVD – Cerebrovascular 
disease, Cerebro-part of brain, Vascular – blood vessels. 
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                JOHN CHEYNE                                    CHARLES BOURCHARD 
 John Cheyne (1777 – 1836) in his cases of apoplexy and lethargy 
distinguished SAH and ICH probably the first physician to provide an 
illustration of SAH. 
 Charles Bourchard (1827 – 1915) was one of the first to provide 
evidence that arterial hypertension might be an important cause of haemorrhages 
in brain.  He also found small leisions resembling tiny globules of grain along 
many penetrating arteries so called military aneurysms were described as one of 
the cause of brain haemorrhage. 
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               HENRY DURET                                 SIR WILLIAMS GOWERS 
 Henry Duret (1849 – 1921) a French Neurosurgeon described the 
anatomy of arteries to brain and identified the common sites of brain infarct and 
haemorrhage along with Charcot he described the anatomy of arteries to brain 
and identified the common sites of brain infarct and haemorrhage along with 
charcot he described the lenticulostriate artery and called it the artery of 
cerebral haemorrhage.  He also studied traumatic brain haemorrhages and 
became aware that many had haemorrhages in upper brainstem near midline so 
called DURET HAEMORRHAGES. 
 Sir Williams Gowers Began his work of ICH by “Haemorrhage is 
always due to rupture of a vessel”.  Sir Miller Fischer, during the middle years 
of 20th century made new clinical and pathologic observations about ICH.  He 
analysed the clinical findings in patients with haemorrhages found at common 
sites for hypertensive ICH such as putamen, Thalamus, Pons and Cerebellum. 
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 The autopsy on Marcello Malphigi, the famous Italian anatomist 
fortuitously solved the mystery of his long standing Right hemiplegia from 
stroke for some years before his death as it revealed haemorrhage into his lateral 
ventricles (Fanyio 1983). 
 The advent of CT Scanning into clinical neurology in 1970s helped to 
greatly expand our knowledge about ICH.  It proved to be an ideal technology 
for the diagnosis of brain haemorrhages. 
 The introduction of MRI in 1980s helped in detection of old haemosiderin 
containing cavities, vascular malformation and three dimensional reconstruction 
of location and dimensions of bleed. 
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CURRENT REVIEW OF LITERATURE 
 In a healthy functioning brain, neurons do not come into direct contact 
with blood.  The vital oxygen and nutrients the neurons need come from the 
blood across the thin walls of cerebral capillaries.  The glia (nervous systems 
cells that support and protect neurons) form a blood brain barrier an elaborate 
meshwork that surrounds blood vessels and capillaries and regulates which 
elements of the blood can pass through the neurons. 
 When an artery in the brain bursts, blood spurts out into the surrounding 
tissue and upsets not only the blood supply, but the delicate chemical balance 
neurons require to function.  This is called a haemorrhagic stroke. 
 Haemorrhages are classified by their location and underlying vascular 
pathology.  Haemorrhagic stroke can be diffuse i.e. bleeding into subarachnoid 
spaces (or) focal (intraparenchymal). 
CAUSES OF ICH 
I. Diffuse haemorrhagic stroke (SAH & IVH): 
This is due to rupture of vessels on or near the surface of brain or 
ventricles. 
1. Aneurysms – Berry, Fusiforus, mycotic  
2. AV malformation 
3. Trauma 
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4. Vasculitis 
5. CNS neoplasms 
6. Haematological disorders like Haemophibia, leukemia, TTP 
II. Focal haemarrhagic  stroke 
 This is due to rupture of arteries that are within the brain substance. 
1. Hypertension 
2. Vascular malformation 
3. Amyloid angiopathy 
4. Anticoagulant therapy 
5. Haematologic disease – leukemia, aplastic anaemia 
6. Drug abuse – cocaine, amphetamine 
7. Neoplasms – Glioblastoma multiforme  
8. Head Injury 
9. Sepsis 
10. Moya moya disease 
The most important modifiable risk factor for IPH is hypertension 
particularly people <55 years, smokers and poor compliance with 
antihypertensives.  People with hypertension have 4 – 6 times increased risk than 
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patients without hypertension.  Excessive alcohol consumption, anticoagulation, 
thrombolysis and various haematologic abnormalaities increase the risk.  
Warfarin anticoagulation to INR 2.5 – 4.5 is associated with ICH – 1%/year.  
Patients treated with tPA have 6.5% risk of ICH compared to placebo – 0.5%.  A 
less well established risk factor is a loco serum cholesterol concentration 
<160mg%.  Advanced age is an independent risk factor. 
PATHOPHYSIOLOGY OF NON-TRAUMATIC IPH 
 It usually results from spontaneous rupture of a small penetrating artery 
deep in the brain occurs predominantly as consequence of chronic uncontrolled 
hypertension.  The extravasation forms a roughly circular or oval mass that 
disrupts the tissue and grows in volume as the bleeding continues.  Adjacent 
brain tissue is distorted and compressed.  The displacement of normal brain 
tissue by haematoma and dissection of blood along fibre tracts account for much 
of the pathology. 
 If the haemorrhage is large, midline structures are displaced to the 
opposite side and reticular activating and respiratory centres are compromised by 
herniation leading to coma and death.  The location and size of the clot and the 
oedema that surrounds the clot determines the degree of upper brainstem 
compression. 
 Blood may dissect into ventricular space and CSF becomes blood in more 
than 90% cases.  A haemorrhage of this type never ruptures through the corten, 
the blood reaching the subarachnoid space via ventricular system. 
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 When haemorrhage is small and located at a distance from ventricles, the 
CSF may remain clear even on repeated examinations.  In first hours and days 
following the haemorrhage oedema accumulates around the clot and adds to the 
mass effect.  Hydrocephalus may occur as a result of bleeding into the 
ventricular system of basal disterns or compression of third ventricle. 
 If the patient survives, the extravasated blood undergoes a predictable 
series of changes.  At first, it clots within hours.  Before the blood clots, red cells 
may settle in the dependend part of the haematoma and form a meniscus with the 
plasma above.  This is particularly prone to occur in anticoagulant induced 
haemorrhage.  Only mass of RBCs and protein are found within the haematoma 
rarely one sees a few remnants of brain tissue.  The haematoma is surrounded by 
petechial haemorrhages from arterioles and venules. 
 Within a few days, Hb products mainly haemosiderin and haematiin 
begin to appear.  The haemosiderin form within histiocytes that have 
phagocytosed RBCs and takes the form of ferritin granules which stain 
positively for iron.  As Oxy Hb is liberated from RBCs and becomes 
deoxygenated Meth Hb is formed.  This hegan within a few days and imparts a 
brownish hue to the periphery of the clot.  Phagocytosis of RBCs begin within 
24 hrs and haemosiderosis is first observed around the margins of the clot in 5 to 
6 days. 
The clot changes colour gradually over a few weeks from dark red to pale 
red and the border of golden brown haemosiderin in due.  The oedema 
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disappears over many days or weeks.  In 2 – 3 months, larger clots are filled with 
a chrome coloured mesh which is slowly absorbed leaving a smooth walled 
cavity. (slit haemorrhages) or a yellow brown scar.  The iron pigment (haematin) 
becomes dispersed and studs adjacent astrocytes and neurons.  It may persist 
well beyond the border of the haemorrhage for years. 
Most hypertensive intraparenchymal haemorrhages develop over 30 to 90 
minutes whereas those associated with anticoagulant therapy may evolve for as 
long as 24 – 48 hours.  The most common sites of non-traumatic 
intraparenchymal haemorrhage in order of frequency are: 
i. Basal ganglia (Putamen and adjacent deep white matter) 
ii. Thalamus  
iii. Central white matter of temporal, parietal, frontal lobes (lobar 
haemorrhage). 
iv. Deep cerebellum 
v. Pons 
About 2% primary haemorrhages are multiple.  Rarely the bleeding is 
solely intraventricular possibly from choroid plexus.  When haemorrhage occurs 
in other brain areas or in non-hypertensive patients greater consideration should 
be given to haemorrhagic disorder, anticoagulant use, neoplasm, vascular 
malformation and causes other than hypertension. 
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POSTMORTEM BRAIN SPECIMEN OF A CASE OF 
INTRACEREBRAL HAEMARRHAGE 
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COMMON SITES OF INTRACEREBRAL HAEMORRHAGE 
 
(A) Cerebral lobes, originating from penetrating cortical Branches of 
the anterior, middle, or posterior cerebral arteries.  
(B) Basal ganglia, originating from ascending lenticulostriate   
branches of the middle cerebral artery. 
(C) The thalamus, originating from ascending thalamogeniculate 
branches of the posterior cerebral artery.  
(D) The pons, originating from paramedian branches of the basilar 
artery 
(E) The cerebellum, originating from penetrating branches of the 
posterior, inferior, anterior inferior, or superior cerebellar arteries.  
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RADIOLOGICAL FINDINGS IN ICH 
CT SCAN: 
CT occupies the foremost position among the lab methods for diagnosis 
of ICH.  This procedure has proved totally reliable in the prediction of 
haemorrhages that are 1 cm or more in diameter.  Smaller pontine haemorrhages 
are usually visualized with less certainity.  At the same time, co-existing 
hydrocephalus, tumors, cerebral swelling and displacement of intracranial 
contents are readily appreciated. 
 In CT scan, fresh blood loss is visualized as a white mass as soon as it is 
shed.  The mass effect and the surrounding extruded serum and oedema are 
hypodense.  After 2 – 3 weeks, the surrounding oedema begins to recede and the 
density of haemoatonea decreases first at the periphery.  Gradually the clot 
becomes isodense with the brain.  There may be a ring of enhancement from the 
haemosiderin filled macrophages and the reacting cells forming the capsule of 
the haemorrhage. 
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LEFT PARIETO OCCIPITAL BLEED 
 
 
LEFT BASAL GANGLIA BLEED SQUASHING LEFT LATERAL 
VENTRICLE 
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CEREBELLAR BLEED 
 
 
 
RIGHT THALAMIC BLEED 
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LEFT PUTAMEN BLEED EXTENDING INTO LATERAL 
VENTRICLES 
 
 
LEFT PUTAMEN BLEED 
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MRI   
 By MRI, either in T1/T2 weighted images, haemorrhage is not easily 
visible in 2/3 after bleeding since Oxy Hb is diamagnetic or at most is slightly 
hypointense so that only the mass effect is evident.  After several days, the 
surrounding oedema is hyperintense in T2 weighted images.  As deoxy Hb and 
Meth Hb form, haematoma signal becomes bright on T1 weighted images and 
dark on T2.  As the haematoma becomes subacute, the dark images gradually 
brighten when Meth Hb disappears and only haemosiderin remains, the entire 
remaining mass is hypodense onT2 weighted images as are the surrounding 
deposits of Fe. 
MRI is particularly useful in demonstrating brainstem haemorrhages and 
residual haemorrhages which remain visible long after they can no longer be 
seen by the CT scan (4 – 5 weeks). 
Intraparenchymal haemorrhages may be described as massive, moderate, 
small, slit and peticheal. 
1. Massive refers to haemorrhage with 7 – 10 cms diameter (or) volume  
>60 ml. 
2. Small referes to haemorrhage with 1 – 2 cm diameter (or) volume <30 ml. 
3. Moderate refers to haemorrhage in between the above two both in 
diameter and volume. 
4. Slit refers to old collapsed HT or traumatic haemorrhage that lies just 
beneath the cortex. 
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COURSE AND PROGNOSIS OF IPH 
 The immediate prognosis of large and medium sized cerebral clots is 
grave i.e. nearly 50% patients die, half of which occurs within first 48 hours 
either the haemorrhage extends into the ventricular system or intracranial 
pressure is elevated to levels that preclude normal perfusion of brain.  
Sometimes the haemorrhage itself seeps into vital centres such as hypothalamus 
or mid brain and results in poor outcome but others may have a good to 
complete recovery if they survive the initial haemorrhage …………….. various 
factors are used to predict the outcome of IPH. 
VOLUME OF BLEED AND PROGNOSIS 
 Supratentorial haemorrhages with volume <30 ml have a good prognosis. 
30 – 60 ml intermediate and >60 ml poor prognosis during initial hospitalization.  
Supratentorial haemorrhages smaller than 30 ml rarely produce death unless they 
are located in the thalamus.  Extenion into ventricles, especially the fourth 
ventricle worsens the prognosis.  Haematomas may expand for several hours 
following the initial haemorrhage, so treating severe hypertension seen 
reasonable to prevent haemotoma progression. 
 Infratentorial haemoatomas >3 cm in diameter have worse prognosis and 
needs surgical evacuation.  In recent series, 30 day case fatality rate of IPH 
averaged 30 – 50%.  Long term prognosis for various degrees of recovery is 
similar to or better than cerebral infarct of same severity. 
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METHOD TO CALCULATE VOLUME OF BLEED 
 Lisch and associates and Kothari and colleagues have estimated the 
volume of IPH.  The formula for an ellipsoid is as follows: 
4/3 π (A/2) (B/2) (C/2) 
 Where A, B, C are the three dimensions of an ellipsoid that approximates 
the IPH.  This formula can be simplified by acknowledging that π is 
approximately 3 and then reducing the formula to: 
ABC / 2 
 For the bedside ABC / 2 method, CT slice with the largest area of 
haemorrhage is identified.  The longest diameter (A) of the haemorrhage on this 
slice is measured.  The diameter perpendicular to A on the same slice is 
measured as (B).  Finally the number of slices upon which haemorrhage is seen 
is multiplied by slice thickness is calculated as the third dimension (C).  If the 
haemorrhage area for a particular slice is greater than 50% of the area seen on 
the slice where the haemorrhage is largest, the slice is considered haemorrhage 
slice for determining C.  If the area is approximately 25 – 75% of the area, the 
slice is considered half a haemorrhagic slice and if the area is <25% of the 
largest haemorrhage, the slice is not considered a haemorrhagic slice.  The CT 
haemorrhagic slice values are then added to determine the value for C.  
Multiplying A,B and C together and dividing by 2 will give the approximate 
volume of IPH.  This method has been shown to be extremely accurate method 
compared with other methods. 
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MAP AND PROGNOSIS 
 Dhandapani et al in a retrospective study examined the relationship 
between blood pressure and outcome in 87 patients after ICH.  Outcome was 
assessed using Glassgow coma score.  Case fatality and combined morbidity and 
mortality rates were reported based on a stratification using cut off MAP of    
145 mmHg in first two hours.  Morbidity and mortality were significantly 
greater among those with MAP greater than 145 mmHg during first two hours 
after presentation.   
 According to Lisch D.Pasteur – W – Rhoades H et al, the three most 
useful indicators in determining the prognosis of patients with IPH appears to be: 
1. Volume of haemorrhage 
2. Level of consciousness upon arrival at emergency department 
3. Presence / absence of intraventricular extension 
On the basis of these three parameters, emergency physicians assist in 
early decision making both for family members and in concert with consultants. 
GCS AND PROGNOSIS 
 The next two predictors are the patients GCS and Pre/absence of IVH.  
Broderich et al developed 9 simple models to predict 30 day mortality after IPH.  
It is mainly applicable to putaminal and thalamic haemorrhage (i.e.) deep 
haemorrhages.  They reviewed the clinical data and CT scans of 188 patients 
with intraparenchymal haemorrhage.  Neurological function at presentation was 
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documented using GCS score and clinical outcomes were graded using a 
modified Oxford Handicap scale. 
 Using 30 day mortality as the dependent variable, they analyzed age, race, 
gender, initial systolic BP, volume of IPH, volume of IVH, initial GCS score, 
location of haemorrhage and surgery using univariate regression analysis and 
found that volume of IPH, volume of IVH and initial GCS score were significant 
predictors of 30 day mortality.  Using the data from their study, the emergency 
physician can determine whether the patients with IPH are at very high risk or 
low risk. 
 In patients with IPH volume >60 ml GCS <8, 30 day mortality = 91% 
 In patients with IPH volume <30 ml, GCS >9, 30 day mortality = 19% 
 Although 19% mortality is still high, it represents a good prognosis for 
IPH. 
 Notably morbidity remains quite high for intraparenchymal haemorrhage.  
In the study of Broderick and colleagues only 1 of 71 patients with IPH volume 
>30 ml could function independently at 30 days. 
LOCATION OF BLEED AND PROGNOSIS 
 As remarked earlier, it is the location of the haematoma, not simply its 
size that determines the clinical effects.  A clot of 60 ml is almost uniformly 
fatal, if situated on basal ganglia but may be relatively benign if located in 
frontal and occipital lobe. 
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HYDROCEPHALUS AND PROGNOSIS 
 From the studies of Biringer and colleagues, it appears that hydrocephalus 
is also an important predictors of poor outcome. 
NIHSS SCORE AND PROGNOSIS 
 Initial severity of stroke often measured by NIHSS score is one of the 
major predictors of poor outcome including mortality after stroke in many 
studies.  Adams H Davis P Leira I et al in their study have shown that NIHSS 
score of 16/higher predicts a high probability of death or severe disability and 
that a score of 6 or less predicts a good recovery. 
 In patients who survive there can be surprising degree of restoration of 
function since in contrast to infarction, haemorrhage has to some extent pushed 
brain tissue aside rather than destroyed it.  Function may return very slowly 
because the extravasated blood takes time to be removed from the tissues.  Also 
since rebleeding from the site is unlikely, patient may live for many years.   
 In some instances, medium sized cerebral and cerebellar haemorrhages, 
patient survives but papilloedema appears after several days of ↑ ICP.  This does 
not mean that the haemorrhage is increasing in size / swelling only that 
papilloedema is slow to develop.  Healed scars impinging on the cortex are liable 
to be epileptogenic. 
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A Prospective Study was done by Yair Lampl, MD., Ronit Gilad; Yehiel 
Eshel Ida Sarova-Pinhas to evaluate neurological and functional outcome after 
spontaneous supratentorial bleeding. The aim of the study was to determine 
whether clinical or neuroradiological parameters could predict the outcome of 
these patients during the first hours of hospitalization. 
Two hundred seventy-nine patients—52 with thalamic, 87 with 
putaminal, and 140 with lobar hemorrhages—were followed prospectively and 
examined on admission and at 2 weeks, 3 months, and 6 months after onset. The 
patients underwent clinical (according to the Glasgow Coma Scale) and 
neuroradiological examinations on admission and were scored clinically and 
functionally (according to Stroke Severity score and Barthel Index) on the 
follow-up periods. Risk factors and the correlation between findings on 
admission and the latest clinical and functional results were calculated with the 
2 test, Pearson correlation test, and Student's t test. Multivariate analysis was 
calculated with the stepwise regression test. 
In all of the bleeding locations, lethal outcome was significantly 
correlated with size of the hematoma (P<.001) and Glasgow Coma Scale score 
on admission (P<.001). Intraventricular blood expansion was found to have a 
better prognosis in thalamic bleeding (P<.007) and a worse prognosis in lobar 
hemorrhage (P<.01). The functional outcome after 6 months was directly 
correlated with the size of the bleeding area in lobar and putaminal hemorrhages. 
No correlation was found in thalamic bleeding. A worse functional outcome was 
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found in putaminocapsular bleeding (P=.004) and in patients with ischemic heart 
disease. A limited better recovery prognosis was found in patients with lobar 
hematoma in the temporal lobe (P=.052). 
The probability of lethal outcome can be calculated on admission in all 
patients with supratentorial bleeding and in correlation with the location and size 
of the bleeding area and level of consciousness. Intraventricular expansion of 
blood is a better prognostic factor in thalamic bleeding and a worse one in lobar 
hematoma. Functional outcome is correlated with size of the bleeding area and 
level of consciousness on admission in putaminal and lobar hemorrhages but has 
no correlation to thalamic hemorrhage.  
All patients were hospitalized in the neurological department 15 minutes 
to 4 hours (mean, 90±140 minutes) after the onset of the first symptoms. The 
patients included had supratentorial bleeding, were of both sexes, and were older 
than 20 years. Patients with recurrent intracerebral hemorrhage, previous stroke, 
or neuroradiological evidence of arteriovenous malformation, brain tumors, or 
predominant subarachnoid hemorrhage and patients receiving anticoagulant 
therapy were excluded from the study. 
All patients were examined clinically and evaluated by two neurologists. 
The follow-up period of each patient observed in this study ended after 6 months 
or by a fatal outcome. Neuroradiological measurements were estimated by a 
neuroradiologist who was not aware of the clinical status of the patients. 
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The following clinical parameters were noted: vascular risk factors; 
hypertension (>170/90 mm Hg; diabetes mellitus (glucose level >140 mg/dL 
preprandial on two examinations, glucose level >200 mg/dL postprandial, or 
HbA1c >8.5%); and ischemic heart disease (proven myocardial infarction, 
existence of multiple lesions on thallium heart isotope screen, or evidence of 
coronary disease on coronary artery catheterization). 
No patient underwent any neurosurgical procedure. All patients were 
treated similarly during hospitalization. Therapy was based on the preservation 
of essential life functions and the prevention of secondary medical 
complications. Intracranial pressure was treated with intravenous mannitol or 
furosemide. 
Clinical evaluations of all patients were done according to the Glasgow 
Coma Scale (GCS) score on admission and after 48 hours, according to the 
Stroke Severity (SS) score, and according to the Barthel Index (BI) on admission 
and at 2 weeks, 3 months, and 6 months after the event. The SS score consisted 
of an examination of mental function (0 to 11 points); motor nerve function, 
including involuntary movements and cerebellar ataxia (0 to 11 points); cranial 
nerve function (0 to 11 points); sensation (0 to 6 points); and reflexes (0 to 5 
points). 
Location and volume of the hematoma were estimated by brain CT scan. 
The examination was made with the use of Elsint CT 2400 Elite with a matrix of 
512. We calculated volume by measuring the areas of high absorption with a 
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tracing cursor in each cut demonstrating bleeding and multiplying by the cut 
thickness. The results were expressed in cubic centimeters. The blood volumes of 
the bottom and top pools were additionally calculated as a special segment.4 5 
The location of the hematoma in thalamic hemorrhages was classified as 
midthalamic, thalamocapsular, paraventricular, posterior thalamic, and 
holothalamic bleedings. The classifications of putaminal hemorrhage included 
pure putaminal, putaminocapsular, putaminothalamic, putaminohemispheric, and 
putaminocapsulohemispheric bleedings. Lobar hematomas were classified as 
frontal, parietal, temporal, parieto-occipital, and huge lobar bleedings. Extension 
of blood into the ventricles was noted. 
The data were analyzed with the 2 test, Pearson correlation test, and 
Student's t test. Multivariate analysis was calculated with the stepwise regression 
test. No significant exceptions were found. 
Fifty-two patients (28 men and 24 women) with thalamic bleeding were 
included in the study (mean age, 66.6±10.6 years). The bleeding locations were 
as follows: 36 holothalamic or diffuse bleeding, 11 thalamocapsular, 8 
midthalamic, 2 posterior thalamic, and one purely paraventricular thalamic 
bleeding. 
The mortality rate was 36.6% (19 patients) during the 6-month follow-up 
period. Causes of patient mortality were as follows: direct result of the bleeding 
(10 patients), rebleeding (1 patient), late complications (8 patients), secondary 
infection (6 patients), and myocardial infarction (2 patients). 
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Eighty-seven patients (60 men and 27 women) were included (mean age, 
69.9±13.6 years). The bleeding locations were as follows: 26 pure putaminal, 24 
putaminocapsulohemispheric, 20 putaminocapsular, and 7 putaminothalamic. 
Among the patients with fatal outcome, the putaminal location was as 
follows: putaminocapsulohemispheric (15 patients), putaminohemispheric (7 
patients), and putaminothalamic (5 patients). No lethal outcome was observed in 
pure and putaminothalamic bleedings. The mortality rate after 6 months was 
31% (27 patients). Causes of mortality were as follows: direct result of the 
bleeding (23 patients) and late complications or secondary infection with sepsis 
(4 patients). 
One hundred forty patients (66 men and 74 women) with lobar 
hematomas were included in this study (mean age, 66.8±11.1 years). The 
locations were as follows: 49 frontal lobe, 42 parietal lobe, 17 temporal lobe, 9 
parieto-occipital lobe, and 23 massive multilobar bleeding. 
The mortality rate after 6 months was 52% (73 patients). All patients with 
massive multilobar hematomas had a fatal outcome. The causes of mortality 
were a direct result of the bleeding (60 patients) and late complications (13 
patients), including intercurrent infectious disease (5 patients), myocardial 
infarction (4 patients), pulmonary embolus (1 patient), and pulmonary edema (1 
patient). In 2 cases the cause could not be determined. (No postmortem 
examination was performed.) 
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In putaminal and thalamic bleedings, no significant correlation was found 
between age or sex and the BI or SS score (P=.29 to .45). In lobar hematomas, 
higher SS scores were found in men (P=.02). No sex or age dependence in the BI 
results was observed. 
Risk factors found in this study were as follows: hypertension (165 
patients; 59%), cigarette smoking (146 patients; 52%), diabetes mellitus (84 
patients; 30%), ischemic heart disease (62 patients; 22%), and hyperlipidemia 
(47 patients; 18%). 
No significant correlation was found between each of the vascular risk 
factors and the outcome. Hypertension and ischemic heart disease had a greater 
tendency toward a reciprocal correlation with poor outcome. Ischemic heart 
disease was found to have a limited reciprocal correlation with BI after 6 months 
only in patients with lobar hematomas (P=.053). 
In thalamic hemorrhage, the mean value of hemorrhage volume was 
16.2±12.0 cm3 (range, 2.8 to 46 cm3). In putaminal hemorrhage, the mean value 
of hemorrhage volume was 26.1±20.1 cm3 (range, 3.1 to 61 cm3). In lobar 
hematomas, the mean value of hemorrhage volume was 55.3±55.2 cm3 (range, 
2.7 to 239 cm3) (frontal lobe, 36.6±22.8 cm3; parietal lobe, 44.9±35.5 cm3; 
temporal lobe, 16.2±13.2 cm3; and parieto-occipital lobe, 16.4±8.2 cm3).  
Significant correlation was found between low GCS score or size of 
hematoma and lethal outcome (P<.001 for each) and between intraventricular 
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penetration and better prognosis for survival (P=.02), especially during the first 
48 hours (P=.0007). The relative risks of probability of death in bleeding without 
intraventricular expansion versus bleeding with intraventricular expansion were 
1.16 for blood volume of 7 cm3 and 2.73 for blood volume of 25 cm3. 
In thalamic hemorrhage no correlation was found between GCS score, 
size of hematoma, or intraventricular expansion and SS score and BI in any stage 
of examination (P=.1 to .54). 
A significant correlation was found between low GCS score or size of 
hematoma and lethal outcome in putaminal haemorrhage. A high significance 
for mortality was found in putaminocapsulothalamic bleeding. Intraventricular 
extension was not found to be a risk factor for poor outcome. The relative risks 
of probability of death, according to a GCS score of 5 versus 11, were 5.3 for a 
blood volume of 5 cm3 and 1.0 for a blood volume of 25 cm3. 
A significant correlation was found between size of bleeding and BI or SS 
score in putaminothalamic, putaminocapsular, and putaminocapsulothalamic 
locations (P=.04, P=.02, and P=.02, respectively). A poor functional outcome 
was found in putaminocapsular and putaminothalamic bleedings (P=.044 and 
P=.051, respectively). No correlation was found between the expansion of blood 
into the ventricle and SS score or BI. 
In lobar haemorrhage size of bleeding area (P<.0036), GCS score 
(P<.0001), and intraventricular extension were significantly correlated with 
 33
lethal outcome. The relative risks of probability of death, according to a GCS 
score of 5 versus 11, were 4.2 for a blood volume of 30 cm3 and 1.7 for a blood 
volume of 100 cm3. 
Significant correlations were found between GCS score or size of 
bleeding on admission and SS score (P<.001 for each) or BI (P<.05 and P<.001, 
respectively). The correlation between intraventricular extension and SS score or 
BI was also significant (P<.01 for each). Temporal lobe bleeding was noted to 
have a somewhat better prognosis compared with other locations (P<.052)  
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MATERIALS AND METHODS 
 All patients with acute stroke admitted in the medical ward of 
Government General Hospital, Chennai from April 2009 to July 2009 were 
investigated for haemorrhagic stroke by obtaining a CT brain. 
INCLUSION CRITERIA 
 Patients with non traumatic intraparenchymal haemorrhage admitted to 
medical wards. 
EXCLUSION CRITERIA 
1. Patients with history of Trauma 
2. Patients with suh arachnoid haemorrhage alone 
3. Patients with intraventricular haemorrhage alone 
4. Patients with previous history of intraparenchymal haemorrhage 
The following data were collected from the patients. 
1. Age 
2. Temperature in  °F at admission 
3. Mean arterial pressure.  This is calculated by: 
a. Mean arterial pressure = Diastolic pressure + 1/3 pulse pressure 
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4. Glassgow coma score at admission to assess the severity of the bleed.  
CT brain was done on the day of admission and the following data 
were collected 
5. Volume of Bleed 
6. Location of Bleed 
7. Presence / Absence of Intraventricular haemorrhage. 
Volume of bleed was calculated using the formula used by Lisch and 
colleagues and Kothari and colleagues. 
i.e Formula for ellipsoid = ABC / 2.  A,B,C are the dimensions. 
CT slices taken in our Government General Hospital are calibrated from 
10 mm / 1 cm thickness.  The slice with largest haemorrhage was found out and 
the largest diameter measured and is taken as ‘A’.  The diameter perpendicular 
to ‘A’ is taken as ‘B’ and ‘C’ is calculated by multiplying the number of 
haemorrhagic slices (n) and thickness of slice (1 cm).  n was calculated by 
adding: 
1 for haemorrhage area of a slice >75% of the largest haemorrhage area 
0.5 for haemorrhage area of a slice 25 – 75% of the largest haemorrhage 
area. 
Haemorrhage area of a slice <25% is not included.  For example: 
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n = slice (1) + slice (2)  + slice (3) 
 =      1      +    0.5      +    0 
n = 1.5  
C = n x slice thickness 
C = 2.5 x 1 
C = 2.5 cm 
 By this method, volume of haemorrhage was calculated for all patients 
included in the study. 
 100 patients were studied similarly to know the outcome at 30 days.  
They were treated with the same regimen in our hospital.  30 days outcome i.e. 
the mortality or the morbidity status using the NIHSS score was done at our 
review OP. 
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RESULTS AND OBSERVATIONS 
 
 Total No. of cases studied   =  100 
 No. of deaths in 30 days   =  51 
 No. of patients survived after 30 days =  49 
 No. of male cases    =  72 
 No. of female cases    =  28 
 No. of Hypertensive cases   =  32 
 No. of non-hypertensive cases  =  68 
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ANALYSIS OF OBSERVATIONS 
TABLE – 1 
AGE AS A PROGNOSTIC PREDICTOR OF IPH 
 
Age group No. of patients No. of deaths Mortality rate (%)
0 – 10 0 0 0 
11 – 20 1 1 100  
21 – 30 0 0 0 
31 – 40 7 4 57.14 
41 – 50 16 4 25 
51 – 60 34 14 41.17 
61 – 70 23 14 60.86 
71 – 80 16 12 75 
81 – 90 3 2 66.66 
91 – 100 0 0 0 
Total 100 51  
¾ The most frequent age group affected is 51 – 60 years in wide range      
41 – 70 years. 
¾ Mortality is high in extremes of age groups, particularly older age group. 
¾ There is no persistent relation between the age and the mortality. 
¾ This may be due to diverse aetiology/coexistent morbidities 
¾ So, age cannot serve as a definite prognostic predictor.
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TABLE – 2 
GENDER AS A PROGNOSTIC PREDICTOR OF IPH
 
Patient Type No. of 
patients 
No. of 
deaths 
Mortality 
rate (%) 
MALES 72 35 48.61 
FEMALES 28 16 57.14 
TOTAL 100 51  
¾ Incidence of intraparenchymal heamorrhage is higher in males. 
¾ Male : Female ≈ 3 : 1. 
¾ But the mortality rate is higher in the females. 
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TABLE – 3 
TEMPERATURE AS A PROGNOSTIC PREDICTOR OF IPH 
 
Temperature No. of 
patients 
No. of deaths Mortality 
Rate (%) 
Temperature >103°F 15 10 66.66 
Temperature <103°F   85 41 48.23 
Total 100 51  
¾ Patients with brainstem bleed had temperature more than 103°F.   
¾ Temperature cannot serve as a prognostic predictor as the values were not 
applicable for bleed in all locations. 
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TABLE – 4 
HYPERTENSION AS A PROGNOSTIC PREDICTOR OF IPH 
Type of Patient  No. of 
patients 
No. of 
deaths 
Mortality 
rate (%) 
Hypertension 32 10 31.25 
Non-Hypertension 68 41 60.29 
Total 100 51  
 
¾ Incidence of IPH is high in patients who are not known hypertensives 
than in known hypertensives. 
¾ Mortality is higher in non-hypertensive IPH. 
¾ This may be explained by: 
i. They are hypertensives not detected earlier. 
ii. Adaptation of the cerebral vessels to the increased pressure in 
known hypertensives. 
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TABLE – 5 
MAP AS A PROGNOSTIC PREDICTOR OF IPH 
 
Type of Patient  No. of 
patients 
No. of 
deaths 
Mortality 
rate (%) 
MAP >145 26 21 80.76 
MAP <145 74 30 40.54 
Total 100 51  
¾ The mortality rate in patients with MAP >145 is almost double that of 
patients with MAP <145. 
¾ So, MAP serves as an important prognostic predictor of 30 day outcome 
in non-traumatic intraparenchymal haemorrhage patients. 
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TABLE – 6 
GCS AS A PROGNOSTIC PREDICTOR OF IPH 
 
Type of Patient  No. of 
patients 
No. of 
deaths 
Mortality 
rate (%) 
GCS <8 57 49 85.96 
GCS >8 43 2 4.65 
Total 100 51  
¾ Higher the GCS score, higher is the survival rate. 
¾ GCS at admission also correlates with the morbidity rate. 
¾ Patients with ↑ GCS score has lesser morbidity i.e. NIHSS <6/42. 
¾ So, GCS can serve as an important predictor of both mortality and 
morbidity of non traumatic IPH. 
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TABLE – 7 
VOLUME OF BLEED AS A PROGNOSTIC PREDICTOR OF IPH 
Type of Patient  No. of 
patients 
No. of 
deaths 
Mortality 
rate (%) 
Volume <30 ml 51 10 19.6 
Volume 30  - 60 ml 37 30 81.08 
Volume >60 ml 12 11 91.66 
Total 100 51  
 
¾ Mortality rate is less when the bleed is less than 30 ml. 
¾ Mortality rate for bleed more than 60 ml  and 30 – 60 ml is more or less 
nearer. 
¾ Bleed less than 30 ml has a good prognosis and more than 30 ml has a 
bad prognosis. 
¾ So, volume of bleed is an important prognostic predictor of non-traumatic 
IPH. 
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TABLE – 8 
LOCATION OF BLEED AS A PROGNOSTIC PREDICTOR OF IPH 
Type of Patient  No. of 
patients 
No. of 
deaths 
Mortality 
rate (%) 
Gangliocapsular 49 23 46.94 
Lobar 24 12 50 
Thalamus 20 10 50 
Brainstem 7 6 85.71 
Total 100 51  
 
¾ Basal ganglia is the most common site of bled followed by the lobar, 
thalamus and brainstem. 
¾ Mortality is high with brainstem haemorrhage. 
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TABLE – 9 
IVH AS A PROGNOSTIC PREDICTOR OF IPH 
Type of Patient  No. of 
patients 
No. of 
deaths 
Mortality 
rate (%) 
IVH (+) 48 40 83.33 
IVH (-) 52 11 21.15 
Total 100 51  
 
¾ Presence of intraventricular haemorrhage carries a poor prognosis. 
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TABLE – 10 
RELATION BETWEEN GCS AND NIHSS SCORE AT 30 DAYS 
Type of 
patient 
No. of 
patients alive
Patients with
NIHSS <6 
Patients with 
NIHSS >6 
Morbidity 
Rate (%) 
GCS <8 8 0 8 100 
GCS >8 41 35 6 15 
Total 49 35 14  
 
¾ GCS is directly related to decreased NIHSS score. 
¾ Higher the GCS, lower the NIHSS score. 
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TABLE – 11 
PROGNOSTIC  PREDICTORS OF  30  DAY MORTALITY IN 
NON-TRAUMATIC IPH 
 
FACTOR 
 
NUMBER OF 
PATIENTS 
 
NUMBER OF 
DEATHS 
 
MORTALITY % 
MAP > 145 26 21 80.76 
GCS < 8 57 49 85.96 
Volume > 60ml 12 11 91.66 
IVH (+) 48 40 83.33 
 
The prognosis predictors of 30 day mortality in non-traumatic IPH patients in order of 
importance according to this study are  
i) Volume > 60ml 
ii) GCS < 8 
iii) Presence of IVH 
iv) MAP >145mm of Hg. 
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PROGNOSTIC  PREDICTORS OF  30  DAY MORTALITY IN 
NON-TRAUMATIC IPH 
 
80.76
85.96
91.66
83.33
74 76 78 80 82 84 86 88 90 92 94
MAP >= 145
GCS <= 8
Volume > 60ml
IVH (+)
MORTALITY %
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DISCUSSION 
MORTALITY RATE: 
 100 patients were included in this study and 51 patients died at the end of 
30 days. The 30 day mortality rate was 51% compared to literature which varies 
from 20 to 60%. 
AGE: 
Intraparenchymal haemarrhage was common in the 50-70yrs age group 
and death was also common in this age group. But Age as such was no found to 
have direct correlation with 30 day mortality. 
GENDER: 
 In our study, IPH was  common in males and it was found that a male has 
a 3 times rish of developing IPH. But the mortality rate was high in females. 
Again this was not a significant prognostic factor in determining 30 day 
mortality. 
TEMPERATURE: 
 Only 15 patients out of 100 patients had temperature above 103F and out 
of them 100 patients died – 8 of them where of Brainstem Bleed. So, 
temperature cannot be applied as a significant prognostic factor in determining 
30 day mortality for IPH in all locations.  
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HYPERTENSION: 
 In 100 patients, 32 patients were known hypertensives and the mortality 
rate was half in the patients compared to the non hypertensives. This may be 
either due to the reason that they are undiagnosed hypertensives or due to the 
difference in the pathogenesis of a acute rise in BP and a chronic rise in BP. 
Further studies regarding the endothelial damage in these patients may clarify 
these queries. 
MAP: 
 Among the 51 dead patients 21 had a MAP of more than 145mm Hg. 
MAP is found to be a more significant predictor than the systolic or diastolic BP. 
GCS: 
 Out of 51 dead patients nearly 49 patients had a GCS score < 8 at 
admission. GCS has got a very strong correlation over the 30 day mortality than 
any other factor. 
VOLUIME OF BLEED: 
 Though a difference is made as mild, moderate and massive bleed, there 
was no significant mortality difference between moderate and massive bleed. 
This may be changed by increased availability if neurosurgical care to some of 
these patients and the mortality can come down. But there was a significant 
reduction in the mortality in patients with bleed < 30ml. 
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LOCATION OF BLEED: 
 Basal ganglia was the common site of Bleed. Nearly 50% cases were 
Basal ganglia Bleed. 25% Lobar Bleed,, 20% Thalamic Bleed and 5% Brainstem 
bleed. According to literature also this was the approximate incidence. In this 
study mortality was higher in Brainstem bleed similar to literature but the 
thalamic bleed did not show a better prognosis as literature. The mortality rates 
of Thalamic Gangliocapsular and Lobar bleed were similar. 
IVH: 
 In literature, Thalamic Bleed with IVH has got a good prognosis 
compared to lobar bleed with IVH. In my study, presence of IVH in any bleed 
carried a poor diagnosis. 
GCS and NIHSS: 
 GCS is the single most important factor in predicting both the mortality 
and morbidity. Patient admitted with high GCS had a low NIHSS score and low 
GCS had a high NIHSS score. 
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ADDITIONAL DATA FROM THE STUDY 
1. Left side bleed is more common than right side. 
2. Diabetes Mellitus is not a common co-morbid condition with 
intracerebral bleed. 
3. Patients who survive the acute stroke in haemorrhage do well than the 
infarct patients. 
4. The common age group is 40 – 60 years. 
5. Incidence of ICH is high in males but the mortality is high in females. 
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CONCLUSION 
 
 Age, Gender, Temperature do not have a significant role in 
detecting the 30 day mortality rate in patients with IPH. 
  i) Volume of Bleed 
ii) GCS at admission 
iii) Presence of  IVH 
iv) Mean Arterial Pressure 
have a significant role in detecting the 30 day mortality in IPH 
patients. 
 Location of bleed at sites other than Brainstem did not have a 
difference in mortality in this study. Studies with larger number of 
patients with different locations of Bleed may throw some light on 
this aspect 
 A case of  stroke with ICH with MAP < 145mm Hg, GCS > 8, 
Volume of Bleed < 30ml, in the absence of IVH has 80% chance 
of survival after 30 days with the best NIHSS score. 
 Early detection of HT and prompt management can prevent the 
occurrence of event. 
ABBREVIATIONS 
 
IPH – Intraparenchymal Haemarrhage 
IVH – Intraventricular Haemarrhage 
GCS- Glasgow Coma Scale 
NIHSS – National Institute of Health System Score 
BP – Blood Pressure 
MAP – Mean Arterial Pressure 
SAH – Sub Arachnoid Haemorrhage 
ICH – Intracerebrak Haemorrhage 
CSF – CerebroSpinal Fluid 
CT – Computed Tomography 
MRI – Magentic Resonance Imaging 
HT – Hypertension 
 
PROGNOSTIC PREDICTORS OF 30 DAY OUTCOME IN PATIENTS 
WITH NON TRAUMATIC INTRAPARENCHYMAL HAEMORRHAGE 
    PROFORMA 
 
S. No :                                                                                    IP No:  
NAME :                                                                                            AGE:                                                
SEX:  M  /  F 
DATE OF ADMISSION:                                                               DATE OF DISCHARGE:                           
WARD/UNIT: 
ADDRESS:                                                                                      OCCUPATION: 
 
 
 
 
CONTACT NUMBER: 
ADMISSION DIAGNOSIS: 
BRIEF HISTORY: 
 
 
 
 
 
 
 
COMORBID ILLNESS:      DM  /   HT   /   IHD  /   BA   /  EPILEPSY 
PERSONAL HISTORY:     Smoker  /   Alcohol  /  Betel leaf   
     PHYSICAL EXAMINATION 
VITAL SIGNS         
PR :   BP :                       MAP=  DP + (1/3)PP =                                          TEMP:  
CENTRAL NERVOUS SYSTEM   :  GCS SCORE                / 15 
EYE OPENING VERBAL RESPONSE MOTOR RESPONSE 
NEVER 1 NO RESPONSE 1 NO RESPONSE 1 
TO PAIN 2 INCOMPREHENSIBLE SOUNDS 2 EXTENSOR RESPONSE TO PAINS 2 
TO VERBAL STIMULI 3 INAPPROPRIATE WORDS 3 FLEXOR RESPONSE TO PAINS 3 
SPONTANEOUSLY 4 DISORIENTED CONVERSES 4 FLEXOR WITHDRAWAL 4 
  ORIENTED AND CONVERSES 5 LOCALISES PAIN 5 
    OBEYS COMMANDS 6 
CVS :                                                              RS :  
ABD :  
INVESTIGATIONS 
CBC      RFT 
 TC :      BLOOD SUGAR : 
 DC :      UREA : 
 Hb % :      SERUM CREATININE : 
 PCV :      Na+ 
 ESR :      K+ : 
 PLATELETS : 
LFT      FASTING LIPID PROFILE 
 TOTAL BILIRUBIN     TOTAL CHOLESTEROL:  
 AST :        TGL :     
 ALT :        HDL : 
 SAP :        LDL : 
 TOTAL PROTEIN : 
BT : 
CT : 
ECG : 
CHEST XRAY PA view : 
ECHO : (If done)  
 
 
 
CT BRAIN 
 SITE OF H’AGE : 
 DIMENSIONS OF H’AGE :  a -  
     b - 
     c -  
              volume of ICH    -    abc/2 =   
 INTRAVENTRICULAR EXTN :        +     /      -  
 MIDLINE SHIFT :                            +      /     - 
 
 
        OUTCOME OF THE PATIENT       :  ALIVE   /    EXPIRED 
                         DATE OF DISCHARGE / DEATH  : 
 
 
 
 
 ASSESSMENT OF 30 DAY OUTCOME BY NIHSS 
ITEM NAME RESPONSE SCORE
1a Level of Consciousness Alert 
Not Alert – responding to minimal stimuli 
Not Alert – responding to repeated stimuli 
Unresponsive 
0 
1 
2 
3 
1b LOC Questions Answers both correctly 
Answers one correctly 
Answers neither 
0 
1 
2 
1c LOC Commands Performs both tasks correctly 
Performs one task correctly 
Performs neither 
0 
1 
2 
2 Gaze Normal 
Partial gaze palsy 
Total gaze palsy 
0 
1 
2 
3 Visual Fields No visual loss 
Partial hemianopia 
Complete hemianopia 
  
0 
1 
2 
4 Facial Palsy Normal 
Minor Paralysis 
Partial Paralysis 
Complete Paralysis 
0 
1 
2 
3 
5a,5b Motor Arm ARM  
No drift                                    
Drift before 10 sec                
R 
0 
1 
L 
0 
1 
Fall before 10 sec               
No drift against gravity      
No movement                     
2 
3 
4 
2 
3 
4 
6a,6b Motor Leg LEG 
No drift                                    
Drift before 5 sec                
Fall before 5 sec               
No drift against gravity      
No movement                     
R 
0 
1 
2 
3 
4 
L 
0 
1 
2 
3 
4 
7 Ataxia Absent 
One limb 
Two limbs 
0 
1 
2 
8 Sensory Normal 
Mild loss 
Severe loss 
0 
1 
2 
9 Language Normal 
Mild aphasia 
Sever aphasia 
Mute/Global aphasia 
0 
1 
2 
3 
10 Dysarthria Normal 
Mild 
Severe 
0 
1 
2 
11 Extinction/inattention Normal 
Mild  
Sever 
0 
1 
2 
  TOTAL   
 
TOTAL NIHSS SCORE : _________  /  42 
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1 George 41767 60 M HT 190/100 130 99 10 R Ganglio capsular 20 - - - - 10 ALIVE
2 Vasantha 43851 40 F - 160/100 120 98.6 10 R Ganglio capsular 14 - - + - 11 ALIVE
3 Arulsamy 43925 50 M - 200/110 140 99 7 L Ganglio capsular 40 - - + - - EXPIRED
4 Veerappan 44819 35 M HT 200/100 133 98.6 5 Brainstem 30 + - + - - EXPIRED
5 Ramachandran 45424 75 M CAD 200/100 133 99.2 6 L Ganglio capsular 37.5 - - + - - EXPIRED
6 Karunanidhi 46101 50 M HT 180/100 126 98.2 9 L Ganglio capsular 8 - - - - 10 ALIVE
7 Ramayee 46912 40 F HT 170/100 123 98.4 10 L Thalamus 10 - - - - 12 ALIVE
8 Kattan 47101 55 M - 190/100 130 98.6 8 L Parietal lobe 6 - - - - 10 ALIVE
9 Selvam 47504 70 M DM/HT/DVT 150/70 97 99.4 15 L Parietal lobe 36 - - - - - EXPIRED
10 Samsudeen 47580 65 M - 220/140 166 99.6 12 R Parieto occipital 23 - - + - 6 ALIVE
11 Chinnaiya 44071 65 M - 220/110 140 98.6 10 L Ganglio capsular 14 - - - - 10 ALIVE
12 Francis 48289 43 M - 200/100 133 98.6 8 L Ganglio capsular 14 - - + - 9 ALIVE
13 Ravi 49580 35 M HT 220/140 166 99 15 L Temporal Lobe 10 - - - - 0 ALIVE
14 Mohana 49587 60 F HT/CAD 220/140 166 99.6 7 R Thalamus 32 + - + - - EXPIRED
15 Thiruvengadam 49524 70 M HT 200/110 140 98.2 10 R Ganglio capsular 24 - - + - 7 ALIVE
16 Saroja 50039 76 F - 160/100 120 98.6 8 R Ganglio capsular 8 - - - - 9 ALIVE
17 Chali 50233 55 M - 200/130 153 100.4 4 Brainstem 25 + - + - - EXPIRED
18 Sainathprasad 50108 64 M HT/CKD 200/120 146 98.2 5 L Ganglio capsular 64 + - + - - EXPIRED
19 Anbarasan 50709 48 M - 180/100 126 98.2 9 Brainstem Cerebellum 18 - - - - 6 ALIVE
20 Palani 50850 53 M - 210/110 143 100 5 R Ganglio capsular 40 + - + - - EXPIRED
21 Ganesh Babu 50943 33 M HT 200/100 140 100 5 L Ganglio capsular 50 + - + - - EXPIRED
22 Neelavathy 50926 65 F HT 250/110 153 104 3 L Thalamus 44 + - + + - EXPIRED
23 Ganapathy 51250 55 M - 220/120 153 98.4 5 R Ganglio capsular 62 - - + - - EXPIRED
24 Kasthuri 51482 50 F HT 190/100 130 100 4 L Ganglio capsular 62 + - + - - EXPIRED
25 Ramadurai 52101 40 M HT 170/100 123 98.2 15 R Parietal lobe 4 - - - - 0 ALIVE
26 Kannan 52098 56 M HT 150/100 116 98.6 10 R Ganglio capsular 6 - - - - 10 ALIVE
27 Saravanan 52916 55 M HT 190/100 130 98.6 10 L Ganglio capsular 6 - - - - 6 ALIVE
28 Munusamy 53250 80 M - 160/80 113 100 5 L Thalamus 46 + - + + - EXPIRED
29 Munusamy 53302 72 M - 180/100 133 100 3 R Parieto occipital 15 - + - - - EXPIRED
30 Ramanaiya 53363 50 M - 160/90 113 98.4 4 L Thalamus 62 + + + + - EXPIRED
31 Thirumalai 53554 45 M - 200/110 140 98.6 9 R Ganglio capsular 10 - - + - 3 ALIVE
32 Prabhu 53984 50 M HT 200/100 133 98.4 11 R Ganglio capsular 8 - - + - 4 ALIVE
33 Loganathan 54174 69 M DM/HT/OLD CVA INF 180/100 123 99.8 3 L Ganglio capsular 64 + - + - - EXPIRED
34 Kalyani 54516 50 F HT 220/130 160 99 15 L Parietal lobe 6 - - - - 0 ALIVE
35 Mohamed Anwar 54860 62 M HT 150/90 110 98 3 L Fronto temporo parietal 64 + - + + - EXPIRED
36 Valli 55303 50 F HT 190/80 113 98.8 7 L Ganglio capsular 45 + - + - - EXPIRED
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37 Bharathy 55405 60 F - 170/100 123 98.8 3 L Ganglio capsular 40 - - + - - EXPIRED
38 Vasudevan 55415 62 M - 200/100 133 98.6 8 L Ganglio capsular 38 + - + - 11 ALIVE
39 Ananda Rao 55825 50 M HT 180/100 123 98.6 9 R Parietal lobe 40 + - + - 10 ALIVE
40 Haneef 55865 65 M - 220/100 140 100 5 L Ganglio capsular 38 - - + - - EXPIRED
41 Andal 56206 75 F - 200/140 160 100 3 R Thalamus 50 + - + - - EXPIRED
42 Ponnusamy 56601 40 M HT 200/100 133 98.6 9 L Thalamus 32 + - + - 14 ALIVE
43 Palani 57297 65 M - 180/110 133 98.6 4 R Ganglio capsular 52 + - + + - EXPIRED
44 Chidambaram 56775 51 M DM 200/110 140 100 4 R Ganglio capsular 50 - - + - - EXPIRED
45 Anaresan 55275 67 M HT 210/100 136 98.6 3 R Fronto parietal 36 + - + - - EXPIRED
46 Jegadeesan 57247 70 M - 200/100 133 100 7 L Ganglio capsular 60 + - + - - EXPIRED
47 Ponnammal 58251 63 F - 230/130 163 99 4 Brainstem 16 + - - - - EXPIRED
48 Munusamy 59044 33 M - 70/40 50 97 3 L Ganglio capsular 50 + + + + - EXPIRED
49 Dhayalan 59207 41 M - 200/100 133 99 10 R Ganglio capsular 15 - - + - 8 ALIVE
50 Babu 59478 37 M HT 180/120 140 99 6 R Thalamus 34 - - - - 15 ALIVE
51 Kamala 59914 65 F - 190/120 153 100 7 Brainstem 10 + - - - - EXPIRED
52 Kothandapani 60105 50 M HT 180/110 143 98.2 15 L Fronto parietal 62 - - + - 0 ALIVE
53 Ramalingam 60904 54 M - 180/100 123 99 9 L Ganglio capsular 8 - - - - 7 ALIVE
54 Sivaraman 61112 50 M HT 190/120 143 98 8 R Ganglio capsular 15 - - + - 8 ALIVE
55 Durai 61267 45 M - 200/120 146 100 6 L Ganglio capsular 48 + - + - - EXPIRED
56 Ramesh 61298 39 M - 200/130 163 101 3 L Parietal 64 + - + - - EXPIRED
57 Ranganathan 61388 45 M - 200/100 133 98.6 8 L Ganglio capsular 10 - - + - - EXPIRED
58 Kannagi 61986 50 F HT 190/100 130 98.6 11 L Ganglio capsular 8 - - - - 5 ALIVE
59 Jaganathan 62705 55 M HT 190/100 130 101 4 L Thalamus 35 + - + - - EXPIRED
60 Ponniah 63101 56 M HT 180/100 123 98.4 11 R Ganglio capsular 8 - - - - 10 ALIVE
61 Pappammal 36746 72 F HT 200/110 140 99.6 4 L Ganglio capsular 63 + - + - - EXPIRED
62 Raja 63276 53 M HT 180/130 146 99 5 L Ganglio capsular 40 + - + - - EXPIRED
63 Ramar 63998 49 M - 190/100 130 98.4 9 R Thalamus 35 + - + - 11 ALIVE
64 Vijaya 64381 50 F HT 150/100 116 98.6 10 R Ganglio capsular 10 - - - - 12 ALIVE
65 Asokan 64894 52 M HT 180/120 140 98.6 15 L Parietal 32 - - + - 0 ALIVE
66 Pushpa 65204 58 F - 220/120 153 98.2 4 L Parieto occipital 38 + - + - - EXPIRED
67 Maragatham 65209 65 F DM/HT 180/100 123 98.4 10 R Fronto parietal 8 - - - - 13 ALIVE
68 Thangavel 65089 50 M - 200/130 163 100 6 R Ganglio capsular 14 - - + - - EXPIRED
69 Chitra 65655 45 F HT 170/110 130 98.6 9 L Ganglio capsular 12 + - + - 7 ALIVE
70 Parimala 65935 51 F - 200/100 133 100 9 R Ganglio capsular 10 - - - - 4 ALIVE
71 Arumugam 65862 52 M - 230/120 156 99.2 12 R Ganglio capsular 20 - - + - 5 ALIVE
72 Parthasarathy 66259 85 M PT 200/90 126 98.4 10 L Ganglio capsular 43 - - + - 6 ALIVE
73 Rani 61218 55 F - 190/140 156 98.6 5 R Temporo parietal 34 + - + - - EXPIRED
74 Kothandam 67268 40 M - 180/120 140 98 5 L Ganglio capsular 60 + - + - - EXPIRED
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75 Babyammal 67347 70 F - 230/110 150 100 3 Brainstem pons 32 + - + - - EXPIRED
76 Aayeesha Bee 67669 49 F HT 150/100 113 99 6 L Thalamus 35 + - + - - EXPIRED
77 Prabhakaran 67991 35 M HT 220/110 146 98.2 15 L Putamen 6 - - - - 0 ALIVE
78 Aayeesha Bee 68019 80 F - 200/120 146 98.4 8 L Thalamus 13 + - + - - EXPIRED
79 Devaraj 67986 50 M HT 150/90 110 98.6 15 L Ganglio capsular 8 - - - - 0 ALIVE
80 Rajamani 67836 60 M - 190/90 123 98.4 15 L Parieto occipital 7 - - - - 0 ALIVE
81 Rajeeh 68070 64 M HT/OLD CVA/INFARCT 200/100 133 105 13 R Thalamus 9 + - + - 3 ALIVE
82 Pachaiyammal 68171 65 F HT 170/100 123 102 3 R Thalamus 36 + - + + - EXPIRED
83 Abdul Basheed 68606 55 M HT 180/100 123 98.6 10 R Thalamus 10 + - + - ALIVE
84 Malakondiah 68600 72 M DM 180/90 120 98.4 9 R Thalamus 8 + - - - ALIVE
85 Punniyakodi 68866 57 M HT 150/110 123 103 3 R Ganglio capsular 40 + - - - - EXPIRED
86 Velayudham 68879 45 M HT 160/100 120 99 15 L Ganglio capsular 6 - - - - 0 ALIVE
87 Raghupathy 69124 70 M - 200/120 176 100 3 L Thalamus 30 - - - - - EXPIRED
88 Parthasarathy 69342 54 M - 180/100 126 98.6 7 L Ganglio capsular 8 - - - - 9 ALIVE
89 Sulochana 69672 47 F DM/HT 160/100 120 98.8 7 L Parietal 10 - - - - 8 ALIVE
90 Chandra Babu 70368 45 M - 200/100 133 98.6 9 R Parietal 6 - - - - 11 ALIVE
91 Mariammal 71205 72 F - 180/130 146 98.8 6 R Temporo parietal 64 + + + - - EXPIRED
92 Munusamy 71407 40 M - 200/130 153 98.6 3 L Temporal parietal 30 - - + - - EXPIRED
93 Durairaj 71411 70 M - 200/120 146 98.6 6 R Temporo parietal 50 + - + - - EXPIRED
94 Vairam 71443 65 M - 150/94 112 99.2 11 R Thalamus 34 + - + - - EXPIRED
95 Vairm 71880 60 F HT 150/90 110 98.6 9 L Parietal 10 - - - - 5 ALIVE
96 Vijayarangam 72224 60 M - 220/120 153 98.8 3 Brainstem Cerebellum 15 + + - - - EXPIRED
97 Sandhya 72589 13 F - 110/80 90 98.2 7 R Ganglio capsular 36 + - + - - EXPIRED
98 Moorthy 72421 95 M HT 150/90 110 99 15 R Ganglio capsular 10 - - - - 0 ALIVE
99 Elumalai 73145 50 M - 200/100 133 98.6 10 L Ganglio capsular 12 - - + - 3 ALIVE
100 Richard 74636 40 M - 220/140 163 105 3 Brainstem 10 + - + - - EXPIRED
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